RSI Oversold Stocks
AYJ.DE is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
VALNEVA SE (AYJ.DE) Stock Price & Overview
FRA:AYJ • FR0004056851
Current stock price
2.569 EUR
-0.13 (-4.92%)
Last:
The current stock price of AYJ.DE is 2.569 EUR. Today AYJ.DE is down by -4.92%. In the past month the price decreased by -43.34%. In the past year, price decreased by -7.52%.
AYJ.DE Key Statistics
52-Week Range2.346 - 5.31
Current AYJ.DE stock price positioned within its 52-week range.
1-Month Range2.55 - 5.04
Current AYJ.DE stock price positioned within its 1-month range.
- Market Cap
- 442.407M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.68
- Dividend Yield
- N/A
AYJ.DE Stock Performance
Today
-4.92%
1 Week
-6.72%
1 Month
-43.34%
3 Months
-40.09%
Longer-term
6 Months -43.54%
1 Year -7.52%
2 Years -24.22%
3 Years -41.23%
5 Years N/A
10 Years N/A
AYJ.DE Stock Chart
AYJ.DE Stock Screens
AYJ.DE currently appears in the following ChartMill screener lists.
AYJ.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to AYJ.DE. When comparing the yearly performance of all stocks, AYJ.DE is a bad performer in the overall market: 91.87% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
AYJ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE. Both the profitability and financial health of AYJ.DE have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AYJ.DE Earnings
On February 19, 2026 AYJ.DE reported an EPS of -0.29 and a revenue of 47.69M. The company missed EPS expectations (-36.73% surprise) and beat revenue expectations (22.64% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-€0.29
Revenue Reported47.687M
EPS Surprise -36.73%
Revenue Surprise 22.64%
AYJ.DE Forecast & Estimates
12 analysts have analysed AYJ.DE and the average price target is 7.38 EUR. This implies a price increase of 187.19% is expected in the next year compared to the current price of 2.569.
For the next year, analysts expect an EPS growth of 52.97% and a revenue growth -2.38% for AYJ.DE
Analysts
Analysts81.67
Price Target7.38 (187.27%)
EPS Next Y52.97%
Revenue Next Year-2.38%
AYJ.DE Groups
Sector & Classification
AYJ.DE Financial Highlights
Over the last trailing twelve months AYJ.DE reported a non-GAAP Earnings per Share(EPS) of -0.68. The EPS decreased by -871.43% compared to the year before.
Income Statements
Revenue(TTM)350.90M
Net Income(TTM)-120.41M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.86% | ||
| ROE | -80.02% | ||
| Debt/Equity | 0.89 |
Chartmill High Growth Momentum
EPS Q2Q%-16%
Sales Q2Q%-9.93%
EPS 1Y (TTM)-871.43%
Revenue 1Y (TTM)41.4%
AYJ.DE Ownership
Ownership
Inst Owners24.55%
Shares172.21M
Float152.14M
Ins Owners0.21%
Short Float %N/A
Short RatioN/A
AYJ.DE Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 26.9 | 40.185B | ||
| ARGX | ARGENX SE | 27.65 | 40.135B | ||
| 22UA | BIONTECH SE-ADR | N/A | 19.953B | ||
| 2X1 | ABIVAX SA | N/A | 7.917B | ||
| ABVX | ABIVAX SA | N/A | 7.881B | ||
| GLPG | GALAPAGOS NV | N/A | 1.624B | ||
| GXE | GALAPAGOS NV | N/A | 1.624B | ||
| NANO | NANOBIOTIX | N/A | 1.24B | ||
| PHARM | PHARMING GROUP NV | 42.84 | 992.13M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 982.019M | ||
| PHGN | PHARMING GROUP NV | 40.91 | 981.96M | ||
| 6IV | INVENTIVA SA | N/A | 981.43M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 967.266M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About AYJ.DE
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
IPO: 2007-06-28
VALNEVA SE
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
Employees: 695
Phone: 33228073710
VALNEVA SE / AYJ.DE FAQ
What does AYJ do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the stock price of VALNEVA SE today?
The current stock price of AYJ.DE is 2.569 EUR. The price decreased by -4.92% in the last trading session.
What is the dividend status of VALNEVA SE?
AYJ.DE does not pay a dividend.
How is the ChartMill rating for VALNEVA SE?
AYJ.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of VALNEVA SE (AYJ.DE) based on its PE ratio?
VALNEVA SE (AYJ.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.68).
What is VALNEVA SE worth?
VALNEVA SE (AYJ.DE) has a market capitalization of 442.41M EUR. This makes AYJ.DE a Small Cap stock.
Can you provide the ownership details for AYJ stock?
You can find the ownership structure of VALNEVA SE (AYJ.DE) on the Ownership tab.